
简介:
- 作者: Lifang Ma, Hui Huang, Wei Feng, Liang Chen, Lili Xia, Yongchun Yu, Jiayi Wang, Yu Chen
- 杂志: Advanced Functional Materials
- Doi: https://www.doi.org/10.1002/adfm.202208220
- 出版日期: 2022 Oct 11
论文中使用的产品/服务
Quotation shows PackGene:CRISPR-Cas9-Mediated HEPH Gene Knock-Out: HEPH-deleted (HEPH−/−) cells were generated using the CRISPR-Cas9-mediated gene knockout technology. Lentivirus-based vectors expressed sg-control and gene-specific sgRNAs targeted HEPH (#1: CTCTGAATGTTCTCTTCCC and #2: TGC TGTTCATTGCAGTCCTTG) were purchased from PackGene (Guangzhou, China).
Research Field:cancer treatment
摘要
The emerging chemodynamic therapy employs an iron-based catalytic Fenton reaction to transform less-reactive endogenous hydrogen peroxide within the tumor microenvironment (TME) into a highly toxic hydroxyl radical for killing cancer cells. However, the effective deployment of chemodynamic modality remains challenging, mired by a paucity of Fenton agents and overexpressed antioxidant glutathione (GSH) in cancer cells. Herein, a clay-based 2D vermiculite nanosheet as a self-reinforcing chemodynamic nanoagent for efficient lung cancer treatment is engineered. The engineered 2D vermiculite nanosheets are not only biocompatible with normal cells but also capable of regulating the TME through depleting GSH, which ameliorates the antioxidant activity of cancer cells. Meanwhile, GSH consumption results in increased intracellular reactive oxygen species content and enhanced lipid peroxidation level, thus inducing ferroptosis and augmenting chemodynamic cell-killing efficacy. In particular, the ferrous oxidase hephaestin is the direct therapeutic target for 2D vermiculite nanosheets to fight against lung cancer cells. Systematic in vivo evaluations on a xenografted tumor model verify the favorable biosafety and effective tumor suppression capacity of the engineered 2D vermiculite nanosheets-mediated chemodynamic tumor therapy by inducing desirable ferroptosis. Therefore, the developed vermiculite nanosheets represent the paradigm of 2D ferroptosis-inducing nanomedicine for synergistic and efficient cancer treatment.
关于派真
作为一家专注于AAV 技术十余年,深耕基因治疗领域的CRO&CDMO,派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付,我们为全球客户提供一站式CMC解决方案,包括从早期概念验证、成药性评估到IIT、IND及BLA的各个阶段。
凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台,我们能将AAV产量提高多至10倍,每批次产量可达1×10¹⁷vg,以满足多样化的商业化和临床项目需求。此外,我们定制化的mRNA和脂质纳米颗粒(LNP)产品及服务覆盖药物和疫苗开发的各个阶段,从研发到符合GMP的生产,提供端到端的一站式解决方案。
